Condition (MeSH)
Dermatitis, Allergic Contact
ClinicalTrials.gov lists 53 trials for Dermatitis, Allergic Contact or a narrower condition beneath it. Allerderm has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
48 of the 53 trials are tagged with Dermatitis, Allergic Contact itself; the rest are tagged with a narrower condition beneath it.
When did Dermatitis, Allergic Contact trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 3 |
| 2024 | 4 |
| 2023 | 4 |
| 2022 | 3 |
| 2021 | 1 |
| 2020 | 3 |
| 2019 | 6 |
| 2018 | 5 |
| 2016 | 1 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Dermatitis, Allergic Contact trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Phase 4 | 5 |
| Not applicable | 23 |
| Observational | 11 |
How many Dermatitis, Allergic Contact trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 1 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 2 |
| Completed | 33 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Dermatitis, Allergic Contact trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Allerderm | 3 |
| Bayer | 2 |
| Mekos Laboratories AS | 2 |
| NeXtGen Biologics, Inc. | 2 |
| Bledina | 1 |
Showing 5 of 6 sponsors.
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Dupilumab/Dupixent | 2 |
| Patch Test | 2 |
| Challenge: Control, irradiation | 1 |
| Infant Formula | 1 |
| 19 organic sunscreen filters and 5 topical NSAIDs | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Dermatitis, Allergic Contact trials report? (5)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Appendicitis | 1 | 1 |
| Dehydration | 1 | 1 |
| Diarrhea | 1 | 1 |
| Sepsis 2nd to Atopic Dermatitis | 1 | 1 |
| Vomiting | 1 | 1 |
Which publications cover Dermatitis, Allergic Contact? (96)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Thresholds for Contact Allergy to a Rubber Accelerator: TETD-Determined by Serial Dilution Patch Testing and a Simulated Glove-Use Model. | Contact dermatitis | 2025 | Yes |
| Allergic Contact Dermatitis to Octyl Cyanoacrylate Skin Glue After Surgical Wound Closure: A Systematic Review. | Dermatitis : contact, atopic, occupational, drug | 2024 | Yes |
| Prevalence and trend of allergen sensitization in patients with a diagnosis of stasis dermatitis referred for patch testing, North American contact dermatitis group data, 2001-2016. | Archives of dermatological research | 2022 | Yes |
| Guidelines for diagnosis, prevention, and treatment of hand eczema. | Contact dermatitis | 2022 | Yes |
| Novel insights into contact dermatitis. | The Journal of allergy and clinical immunology | 2022 | Yes |
Showing 5 of 96 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.